Abstract
Objective To evaluate the frequency, duration and patterns of long-term coronavirus disease 2019 (COVID-19) symptoms and to analyze risk factors for long-lasting COVID-19 sequelae among hospital employees (HEs).
Design Retrospective observational cohort study.
Setting Three medical centers in Cologne, Germany.
Participants We included HEs who had a positive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) polymerase chain reaction (PCR) test between March 2020 and May 2021.
Methods We conducted a survey in mid-2021 with all HEs tested SARS-CoV-2 PCR positive during the study period and asked about the presence and duration of 24 different COVID-19 related symptoms. Chronological development and patterns of symptom complexes, probability of symptom persistence and possible risk factors for protracted COVID-19 course were analyzed.
Results Of 221 included HEs, a number of 104 HEs (47.1%) reported at least one persisting symptom for more than 90 days after initial SARS-CoV-2 detection. A symptom duration over 28 days was associated with multiple symptom complexes. The most common was the interrelated occurrence of shortness of breath, memory disorder, concentration disorders and fatigue. Each one cycle higher initial Ct value significantly increased the chances of overcoming symptoms (odds ratio [OR] = 1.05; p = 0.019). The occurrence of breathlessness within the first ten days (OR = 7.89; p = 0.008), an initial Ct value under 30 (OR = 3.36; p = 0.022) and a definitely nosocomial SARS-CoV-2 transmission (OR = 3.05; p = 0.049) showed a statistically significant association with increased odds of illness duration over 90 days.
Conclusion About half of the HEs suffered from long lasting symptoms over 90 days after almost entirely mild acute COVID-19. Different symptom complexes could be shown and predictive factors for long-term symptoms were identified. Predictive factors at the onset of the infection could possibly be used for early treatment to prevent development of long-term symptoms after COVID-19 in future.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any external funding. The study was core funded.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The ethics committee of the Witten/Herdecke University gave ethical approval for this work (S 273/2021).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
